ZNTL: zentalis.com Company Cumulative Debt

Brandmark of Zentalis Pharmaceuticals, Inc. (ZNTL)

Zentalis Pharmaceuticals (ZNTL) relies on significant pricing power driven by its unique Wee1 inhibitor. However, the risk of clinical trial failures and pressure from generics create financial instability. Institutional capital continues to support targeted therapy while the FDA examines molecular toxicity. The level of financial debt clearly reflects the credit burden, where the value of 0.04 describes the company's current borrowing level.

Company Debts: Zentalis Pharmaceuticals (ZNTL) for 07/04/2022 - 11/01/2026

Zentalis (ZNTL) - metric breakdowns and financial figures

- share price and consensus valuation forecast:
Price Performance Chart Zentalis Pharma|ZNTL - Analyst Consensus Forecast
- market capitalization information:
Market Value Zentalis Pharmaceuticals Inc|ZNTL - Enterprise Value
- shareholders' equity book value data:
Book Value per Share Zentalis|ZNTL - Company Book Value|Market Capitalization to Book Value zentalis.com|ZNTL - Cumulative Company Assets
- debt obligations and liquidity statistics:
Aggregate Debt to Capital Zentalis Pharmaceuticals|ZNTL - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Zentalis Pharmaceuticals, Inc.|ZNTL - Company Aggregate Debts|Debt to Book Value Zentalis Pharmaceuticals Inc|ZNTL - Company Long-Term Debts|Company Short-Term Debts Zentalis|Immediate Liquidity Ratio zentalis.com
- company profitability and valuation multiples indicators:
ZNTL - Net Profit
General company analysis:ZNTL (Zentalis Pharma)
Brand item of Zentalis Pharmaceuticals, Inc.

This indicator measures the total debt burden by aggregating the market consensus across all borrowed credit resources to assess the issuer's financial stability. By analyzing the leverage ratio at 0.04, an investor can see the balance sheet stability of Zentalis Pharmaceuticals (ZNTL), which is supported by the predictable US legal regime and the international status of oncology research, minimizing geopolitical risks.

Competing companies

OLMA (Olema Corp) - Aggregate Debt Obligations|Company Aggregate Debts PBYI (Puma Biotechnology, Inc.)|greenwichlifesciences.com (GLSI) - Company Cumulative Debt|MacroGenics - Company Aggregate Debts|PSTV - Company Aggregate Debts|processapharmaceuticals.com (PCSA) - Company Debts|EGRX - Company Total Debt Obligations